Skyviews is a privately held advisory company specialised in precision health and longevity. We identify investment opportunities at the growing interface between biotechnology, advanced nutrition and digital health. We target private and public companies with better drugs, advanced technology platforms, preventive strategies, personalized solutions and more natural foods that will improve people’s quality of life. We are a team of experienced professionals from the academic, corporate, consumer and venture capital sectors. We leverage worldwide networks and work closely with partner organizations to identify outstanding value for our clients, for patients, for healthcare payors and for capital. Our perspective is rooted in “P4 medicine”, evolving from reactive disease care to care that is predictive, preventive, personalized and participatory. This new paradigm focuses on big data, better lifestyles and tailored treatments, building on the evidence that each individual’s health experience is unique.
13
Total Investments
10
Portfolio Companies
-
Exits
1
Industries
General Information
Industries
Health Care
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Skyviews Life Science
Recent Investments (13)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Post Ipo Equity | •••••• | Feb 2023 | |
| Series A | •••••• | Oct 2022 | |
| Series C | •••••• | Jul 2022 | |
| Series A | •••••• | Apr 2022 | |
| Series D | •••••• | Jul 2021 | |
|
|
Series B | •••••• | May 2021 |
|
|
Seed Round | •••••• | Mar 2021 |
|
|
Series B | •••••• | Jan 2021 |
|
|
Series B | •••••• | Dec 2020 |
|
|
Series B | •••••• | Jun 2020 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.